Acivicin

Acivicin （Aladdin A134970）Is a heterocyclic analog of L-glutamate, first isolated from Streptomyces sviceus. It possesses both antimicrobial and anticancer properties.

• This compound acts as an inhibitor of γ-glutamyltranspeptidase (γ-GT), an enzyme located in the cell membranes of the kidneys, heart, brain, and pancreas that transfers γ-glutamyl groups. γ-GT plays a key role in amino acid transport across membranes and in maintaining oxidative stress balance. Acivicin binds covalently to the enzyme’s active site, triggering a conformational shift that causes the C-terminal domain to fold over and obstruct substrate entry and product release. This structural change effectively halts the enzyme’s catalytic activity. Since glutathione is hydrolyzed by γ-GT, acivicin is frequently used as a tool to investigate glutathione metabolism and homeostasis.
• In addition to γ-GT inhibition, acivicin targets glutamine amidotransferases, including GMP synthase and IGP synthase. It has been shown to suppress the proliferation of hepatoma cells in vitro by preventing uridine and thymidine incorporation into macromolecules, leading to reduced intracellular pools of CTP, GTP, dCTP, dGTP, and tTTP. In the same study, acivicin also inhibited CTP synthase. Other research reports a broader depletion of all nucleoside triphosphate pools.
• Acivicin has also demonstrated chemotherapeutic potential in clinical trials, though its therapeutic utility has been restricted by central nervous system (CNS) toxicity. It has been explored as a low-dose adjunct to other anticancer agents, including cisplatin, since γ-GT inhibition can reduce cisplatin-induced kidney damage.
• The compound’s ability to inhibit GMP synthase further reduces the virulence of pathogenic fungi such as Candida albicans and Aspergillus fumigatus. Structural analogs of acivicin are currently being investigated for antiparasitic applications, particularly due to their enhanced binding affinity for CTP synthase.

References:

1. Williams K, Cullato S, Sand A, et al. Biochemistry. 2009 Mar 24;48(11):2459-67.

2. Lui MS, Kizaki H, Weber G. Biochem Pharmacol. 1982 Nov 1;31(21):3469-7

3. Weber G, Natsumeda Y, Lui MS, et al. Adv Enzyme Regul. 1984;22:69-93.

4. Hidalgo M, Rodriguez G, Kuhn JG, et al. Clin Cancer Res. 1998 Nov;4(11):2763-70.

5. Hanigan MH, Gallagher BC, Taylor PT Jr. Am J Obstet Gynecol. 1996 Aug;175(2):270-4.

6. Rodriguez-Suarez R, Xu D, Veillette K, et al. Chem Biol. 2007 Oct;14(10):1163-75.

7. Tamborini L, Pinto A, Smith TK, et al. ChemMedChem. 2012 Sep;7(9):1623-34.

Aladdin: https://www.aladdinsci.com/